CLEVIPREX® (clevidipine) is recommended in the 2018 AHA/ASA AIS Guidelines*1


Learn about CLEVIPREX® (clevidipine) titratable dosing

The Guidelines for the Early Management of Patients With Acute Ischemic Stroke (AIS) have been updated to include CLEVIPREX as an option for lowering arterial hypertension before, during, and after acute reperfusion therapy.*1

For an AIS patient who is otherwise eligible for acute reperfusion therapy except that BP is >185/110 mmHg
Treatment options
Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2–5 min until desired BP reached; maximum 21 mg/h; or
Labetalol 10–20 mg IV over 1–2 min, may repeat 1 time; or
Nicardipine 5 mg/h IV, titrate up by 2.5 mg/h every 5–15 min, maximum 15 mg/h; when desired BP reached, adjust to maintain proper BP limit
Other agents (eg, hydralazine, enalaprilat) may also be considered
For an AIS patient who has either SBP >180–230 mmHg or DBP >105–120 mmHg
Treatment options
Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2–5 min until desired BP reached; maximum 21 mg/h; or
Labetalol 10 mg IV followed by continuous IV infusion 2–8 mg/min; or
Nicardipine 5 mg/h IV, titrate up to desired effect by 2.5 mg/h every 5–15 min, maximum 15 mg/h
If BP not controlled or DBP >140 mmHg, consider IV sodium nitroprusside

*Recommendation Class IIb (benefit ≥ risk); Level of Evidence C-EO (consensus of expert opinion based on clinical experience).

†Different treatment options may be appropriate in patients who have comorbid conditions that may benefit from acute reductions in BP such as acute coronary event, acute heart failure, aortic dissection, or preeclampsia/eclampsia.

Neither CLEVIPREX nor CARDENE I.V. is indicated for the prevention or treatment of AIS.

Stroke Guidelines Summary

Would you like a summary of the 2018 AHA/ASA AIS Guidelines recommendations on CLEVIPREX?